The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized
The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.
대표청구항▼
It is claimed: 1. A composition for delivery of aminoglycoside to the lungs, the composition comprising a volume of particles that forms a respirable unit dose, the particles comprising aminoglycoside, a bulk density of greater than 0.08 g/cm3, a geometric diameter of less than 5 microns, and a mas
It is claimed: 1. A composition for delivery of aminoglycoside to the lungs, the composition comprising a volume of particles that forms a respirable unit dose, the particles comprising aminoglycoside, a bulk density of greater than 0.08 g/cm3, a geometric diameter of less than 5 microns, and a mass median aerodynamic diameter of less than 5 microns; wherein the volume of particles that forms a respirable unit dose is equivalent to, or less than, a capsule volume corresponding to a size #00 capsule, and wherein administration of less than 6 of the respirable unit doses is effective to provide at least 27.6 mg of aminoglycoside to the lungs. 2. A composition according to claim 1 wherein the particles comprise a pharmaceutically acceptable excipient. 3. A composition according to claim 2 wherein the pharmaceutically acceptable excipient comprises a dispersing agent selected from the group consisting of hydrophobic amino acids and water soluble polypeptides. 4. A composition according to claim 3 wherein the dispersing agent comprises a hydrophobic amino acid selected from the group consisting of alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, valine and combinations thereof. 5. A composition according to claim 3 wherein the dispersing agent comprises leucine. 6. A composition according to claim 1 wherein the aminoglycoside comprises a potency of greater than 60%. 7. A composition according to claim 1 wherein the aminoglycoside is selected from the group consisting of gentamicin, netilmicin, paramecin, tobramycin, amikacin, kanamycin, neomycin, streptomycin and their salts and combinations thereof. 8. A composition according to claim 1 having a residual moisture content of below about 15% by weight. 9. A composition according to claim 1 wherein the particles have a geometric diameter from 0.5-5 microns. 10. A composition according to claim 1 wherein the mass median aerodynamic diameter is from 1-4 microns. 11. A composition according to claim 1 wherein the respirable unit dose provides an emitted dose of at least 70%. 12. A composition According to claim 1 wherein the aminoglycoside comprises at least 75% w/w tobramycin or salt thereof. 13. A composition according to claim 1 wherein the aminoglycoside comprises at least 85% w/w tobramycin or salt thereof. 14. A composition according to claim 12 further comprising up to 20% w/w of a phospholipid. 15. A composition according to claim 12 wherein the particles comprise a bulk density of greater than 0.10 g/cm3. 16. A composition according to claim 1 wherein the particles comprise a hollow and porous morphology. 17. A composition according to claim 12 comprising a tobramycin potency of greater than 60%. 18. A spray dried composition according to claim 1 wherein the particles are formed by spray drying. 19. A method for administering aminoglycoside to the lungs, said method comprising administering by inhalation the composition of claim 1 in aerosolized form. 20. A method for administering aminoglycoside to the lungs, said method comprising administering by inhalation the composition of claim 5 in aerosolized form. 21. The composition of claim 19 wherein said composition is administered by an inhaler device. 22. A respirable composition comprising a volume of particles for delivery of aminoglycoside to the lungs of a patient, the particles comprising (i) aminoglycoside, (ii) phospholipid, (iii) a bulk density of greater than 0.08 g/cm3, (iv) a geometric diameter of 1 to 5 microns, and (v) a mass median aerodynamic diameter of less than 5 microns, wherein the volume of particles forms a respirable unit dose and the volume of particles is equivalent to, or less than, a capsule volume corresponding to a size #2 capsule, and wherein administration of less than 6 of the respirable unit doses to the patient is effective to provide at least 27.6 mg of aminoglycoside to the lungs of the patient. 23. A composition according to claim 22 wherein the composition comprises a bulk density of greater than 0.10 g/cm3. 24. A composition according to claim 22 capable of providing at least 27.6 mg of the aminoglycoside to the lungs via 4 respirable unit doses or less. 25. A composition according to claim 22 wherein the aminoglycoside or salt thereof is present in an amount corresponding to 10-60 mg/unit dose. 26. A composition according to claim 22 wherein the aminoglycoside or salt thereof is present in an amount of at least 50% by weight. 27. A composition according to claim 22 wherein the aminoglycoside or salt thereof is present in an amount of at least 80% by weight. 28. A composition according to claim 22 wherein the aminoglycoside is selected from the group consisting of gentamicin, netilmicin, paramecin, tobramycin, amikacin, kanamycin, neomycin, streptomycin and their salts and combinations thereof. 29. A composition according to claim 22 wherein the aminoglycoside comprises at least 75% w/w tobramycin or salt thereof. 30. A composition according to claim 22 wherein the particles comprise 2-25 w/w % of the phospholipid. 31. A composition according to claim 22 wherein the particles comprise a metal ion. 32. A composition according to claim 22 wherein the particles comprise calcium chloride. 33. A composition according to claim 22 wherein the particles comprise spray dried particles having a hollow and porous morphology. 34. A composition according to claim 22 wherein the fill mass of the composition in a unit dose capsule is within 20-100 mg per capsule. 35. A composition according to claim 22 wherein the fill mass of the composition in a unit dose capsule is within 25-60 mg per capsule. 36. A method for administering an aminoglycoside to the lungs, said method comprising administering by inhalation the composition of claim 22 in aerosolized form. 37. A method for administering an aminoglycoside to the lungs to reduce the potential for development of bacteria in the lungs, the method comprising administering by inhalation the composition of claim 22 in aerosolized form, in a course of treatment which is performed over a plurality of days. 38. A composition for delivery of aminoglycoside to the lungs, the composition comprising a volume of particles that forms a respirable unit dose, the particles comprising aminoglycoside, a bulk density of greater than 0.08 g/cm3, a geometric diameter of less than 5 microns and a mass median aerodynamic diameter of from 1-4 microns; wherein the volume of particles that forms a respirable unit dose is equivalent to, or less than, a capsule volume corresponding to a size #00 capsule, and wherein administration of less than 6 of the respirable unit doses provides a therapeutically effective dosage of aminoglycoside to the lungs. 39. A composition according to claim 38 wherein the aminoglycoside comprises a potency of greater than 60%. 40. A composition according to claim 38 wherein the aminoglycoside is selected from the group consisting of gentamicin, netilmicin, paramecin, tobramycin, amikacin, kanamycin, neomycin, streptomycin and their salts and combinations thereof. 41. A composition according to claim 38 wherein the particles have a residual moisture content of below about 15% by weight. 42. A composition according to claim 38 wherein the particles have a geometric diameter from 0.5-5 microns. 43. A composition according to claim 38 wherein the aminoglycoside comprises at least 75% w/w tobramycin or salt thereof. 44. A composition according to claim 38 wherein the particles comprise up to 20% w/w of a phospholipid. 45. A composition according to claim 38 wherein the particles comprise a hollow and porous morphology. 46. A composition according to claim 38 wherein the aminoglycoside comprises tobramycin in a potency of greater than 60%. 47. A spray dried composition according to claim 38 wherein the particles are formed by spray dying. 48. A method for administering aminoglycoside to the lungs, the method comprising administering by inhalation the composition of claim 38 in aerosolized form. 49. The method of claim 48 wherein the composition is administered in aerosolized form by an inhaler device.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (140)
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Fu Lu Mou-Ying (Lake Bluff IL) Adjei Akwete L. (Wadsworth IL) Gupta Pramod K. (Gurnee IL), Aerosol drug formulations containing polyglycolyzed glycerides.
Duan Daniel C. (St. Paul MN) Stefely James S. (Woodbury MN) Schultz David W. (Pine Springs MN) Leach Chester L. (Lake Elmo MN), Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid.
Duan Daniel C. ; Stefely James S. ; Schultz David W. ; Leach Chester L., Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing propellant 134a and fluticasone propionate.
Evans Richard M. (Westwood MA) Farr Stephen J. (Llandaf GB7), Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol.
Sekins K. Michael (San Diego CA) Shaffer Thomas H. (Lansdowne PA) Wolfson Marla R. (Wyndmoor PA), Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation.
Bonte Frdric (Boulogne FRX) Dehan Michel (Verrieres le Buisson FRX) Le Ridant Alain (Neuilly sur Seine FRX) Puisieux Francis (Maisons Alfort FRX) Taupin Christiane C. (Orsay FRX), Artificial surfactants, pharmaceutical compositions containing them and use thereof.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann,GB3 ; Taylor Anthony James,GB3 ; Wyatt David Andrew,GB3, Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canisters containing aerosol formulations containing P134a and fluticasone propionate.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Trevino Leo A. (San Diego CA) Dellamary Luis A. (San Marcos CA) Tarara Thomas E. (San Diego CA) Weers Jeffry G. (San Diego CA) Ranney Helen M. (La Jolla CA), Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents.
Platz Robert M. ; Patton John S. ; Foster Linda C. ; Eljamal Mohammed,LBX, Dispersible antibody compositions and methods for their preparation and use.
Illum Lisbeth (Nottingham GBX), Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving mater.
Fuhrman Bradley P. (Buffalo NY) Flaim Stephen F. (San Diego CA) Hernan Lynn J. (Buffalo NY) Nesti Frances D. (Shelburne VT) Papo Michele C. (Buffalo NY) Steinhorn David M. (Eggertsville NY), Fluorocarbons as anti-inflammatory agents.
Byron Peter R. (Richmond) Dalby Richard N. (Richmond VA), Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Byron Peter R. (Richmond VA) Dalby Richard N. (Richmond VA), Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Kaufman Robert J. ; Richard Thomas J. ; Stephens Richard A. ; Goodin Thomas H. ; Allen John S. ; Layton Tony E., Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal.
Cloosterman Aloysius B. M. (Emmerich DEX) Kranenburg Simon V. (Ijssel NLX), Lipid and protein containing material in particulate form and process therefor.
Villax Peter (Lisbon PTX) Peres Rui (Cascais PTX) Treneman William Richard (Cambs GB3) McDerment Iain Grierson (Herts GB3) Bunce Martin (London GB3), Medicament inhaler and method.
Byron Peter R. (Richmond VA) Blondino Frank E. (Richmond VA), Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable.
Johansson Eric T. ; Ritson Carl ; Rubsamen Reid M., Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissue and controlling their r.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
Greenleaf David J. (Loughborough GB3) Purewal Tarlochan S. (Leamington Spa GB3) Jinks Philip A. (Mount Sorrel GB3), Method for preparing medicinal aerosol formulation containing coated medicament.
Lichtenberger Lenard M. (Houston TX 4), Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy.
Platz Robert M. ; Kimura Shigenobu,JPX ; Satoh Yu-ichiro,JPX ; Foster Linda C., Methods and compositions for the dry powder formulation of interferons.
Johnson Keith A. (Sunnyvale CA) Gordon Marc S. (Sunnyvale CA) Lyons Shirley W. (Sunnyvale CA), Methods and system for processing dispersible fine powders.
Unger Evan C. ; Fritz Thomas A. ; Matsunaga Terry ; Ramaswami VaradaRajan ; Yellowhair David ; Wu Guanli, Methods of preparing gas and gaseous precursor-filled microspheres.
Egan Edmund A. ; Holm Bruce A. ; Ferguson William H., Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction.
Bernstein Howard (Cambridge MA) Zhang Yan (Cambridge MA) Khan M. Amin (Downingtown PA) Tracy Mark A. (Arlington MA), Modulated release from biocompatible polymers.
Fassberg Julianne (New York NY) Sequeira Joel A. (New York NY) Chaudry Imtiaz A. (North Caldwell NJ) Kopcha Michael (East Brunswick NJ), Non-chlorofluorocarbon aerosol formulations.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Rubsamen Reid ; Gonda Igor ; Farr Stephen ; Cipolla David, Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of und.
Sutton Andrew D. (Ruddington GB2) Johnson Richard A. (West Bridgford GB2) Senior Peter J. (Near Melbourne GB2) Heath David (The Park GB2), Preparation of diagnostic agents.
Osborne Nicholas,GBX ; Sutton Andrew Derek,GBX ; Johnson Richard Alan,GBX, Preparation of hollow microcapsules by spray-drying an aqueous solution of a wall-forming material and a water-miscible.
Platz Robert M. (Half Moon Bay CA) Winters Mark A. (Mountain View CA) Pitt Colin G. (Thousand Oaks CA), Pulmonary administration of granulocyte colony stimulating factor.
Manning Mark C. ; Randolph Theodore W. ; Shefter Eli ; Falk ; III Richard F., Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the s.
Wong Sui-Ming (Collegeville PA) Newington Ian M. (Hazlemere GB2) Liversidge Elaine M. (West Chester PA) McIntire Gregory L. (West Chester PA) Pitt Alan R. (Sandridge GBX) Shaw Jack M. (Aberdeen MD), Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Systemic administration of a therapeutic preparation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Systemic administration of a therapeutic preparation.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic delivery systems related applications.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic drug delivery systems.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Sakon Kiyoyuki,JPX ; Sakagami Masahiro,JPX ; Makino Yuji,JPX ; Suzuki Yoshiki,JPX ; Kobayashi Hideki,JPX, Ultrafine particle power for inhalation and method for production thereof.
Schultz Robert K. (Shoreview MN) Quessy Stephen N. (St. Paul MN), Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations.
Adamo, Benoit; Polidoro, John M.; Overfield, Dennis; Sahi, Carl R.; Laurenzi, Brendan; Smutney, Chad C.; Kinsey, P. Spencer, Apparatus and method for simulating inhalation efforts.
Smutney, Chad C.; Adamo, Benoit; Polidoro, John M.; Kinsey, P. Spencer; Overfield, Dennis; Sahi, Carl R.; Billings, Christine; Marino, Mark T., Dry powder drug delivery system.
Smutney, Chad C.; Adamo, Benoit; Polidoro, John M.; Kinsey, P. Spencer; Overfield, Dennis; Sahi, Carl R.; Billings, Christine; Marino, Mark T., Dry powder drug delivery system.
Smutney, Chad C.; Adamo, Benoit; Polidoro, John M.; Kinsey, P. Spencer; Overfield, Dennis; Sahi, Carl; Billings, Christine; Marino, Mark T., Dry powder drug delivery system and methods.
Smutney, Chad C.; Adamo, Benoit; Polidoro, John M.; Kinsey, P. Spencer; Overfield, Dennis; Sahi, Carl; Billings, Christine; Marino, Mark T., Dry powder drug delivery system and methods.
Smutney, Chad C.; Kinsey, P. Spencer; Sahi, Carl R.; Adamo, Benoit; Polidoro, John M.; McLean, Scott; Overfield, Dennis; Bryant, Anthony, Dry powder inhaler and system for drug delivery.
Smutney, Chad C.; Kinsey, P. Spencer; Sahi, Carl R.; Adamo, Benoit; Polidoro, John M.; McLean, Scott; Overfield, Dennis; Bryant, Anthony, Dry powder inhaler and system for drug delivery.
Smutney, Chad C.; Kinsey, P. Spencer; Sahi, Carl R.; Adamo, Benoit; Polidoro, John M.; McLean, Scott; Overfield, Dennis; Bryant, Anthony, Dry powder inhaler and system for drug delivery.
Smutney, Chad C.; Kinsey, P. Spencer; Sahi, Carl R.; Adamo, Benoit; Polidoro, John M.; McLean, Scott; Overfield, Dennis; Bryant, Anthony; He, Tom; Mann, Alfred, Dry powder inhaler and system for drug delivery.
Smutney, Chad C.; Kinsey, P. Spencer; Sahi, Carl R.; Adamo, Benoit; Polidoro, John M.; McLean, Scott; Overfield, Dennis; Kraft, Kelly S.; Somerville, Karla, Dry powder inhaler and system for drug delivery.
Smutney, Chad C.; Kinsey, P. Spencer; Sahi, Carl R.; Adamo, Benoit; Polidoro, John M.; McLean, Scott; Overfield, Dennis; Kraft, Kelly S.; Somerville, Karla, Dry powder inhaler and system for drug delivery.
Smutney, Chad C.; Kinsey, P. Spencer; Sahi, Carl R.; Adamo, Benoit; Polidoro, John M.; McLean, Scott; Overfield, Dennis; Kraft, Kelly S.; Somerville, Karla, Dry powder inhaler and system for drug delivery.
Smutney, Chad C.; Kinsey, P. Spencer; Sahi, Carl R.; Adamo, Benoit; Polidoro, John M.; McLean, Scott; Overfiled, Dennis; Bryant, Anthony, Dry powder inhaler and system for drug delivery.
Smutney, Chad C.; Kinsey, P. Spencer; Sahi, Carl R.; Adamo, Benoit; Polidoro, John M.; McLean, Scott; Overfileld, Dennis; Bryant, Anthony; He, Tom; Mann, Alfred, Dry powder inhaler and system for drug delivery.
Smutney, Chad C.; Leone-Bay, Andrea; Galarza, Jose M.; Munoz, Hector; Martin, George R.; Grant, Marshall L., Inhalable vaccine compositions and methods.
Overfield, Dennis; Sahi, Carl R.; Adamo, Benoit; Kinsey, P. Spencer; McLean, Scott; Polidoro, John M.; Smutney, Chad C., Interactive apparatus and method for real-time profiling of inhalation efforts.
Oberg, Keith A.; Sulner, Joseph; Grant, Marshall L., Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents.
Oberg, Keith A.; Sulner, Joseph; Grant, Marshall L., Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.